Abstract | OBJECTIVE: To examine the efficacies and adverse events of low-dose tacrolimus in intractable myasthenia gravis (MG) patients during a long-term follow-up. METHODS: RESULTS: (1) All patients were followed up for 7 - 23 months. Adverse events occurred in 6 patients (16.67%). (2) The myasthenic symptoms improved up to the levels of MG- ADL and MGFA in 24 patients (66.67%). There was notable statistical significance in the comparison of clinical status at pre- and post-treatment (P = 0.000). (3) The efficacies in patients with generalized MG were better than those with ocular MG (P = 0.032). (4) The average blood trough levels of tacrolimus were lower than the recommended maintenance range from other countries in 24 effective patients. CONCLUSION: The administration of tacrolimus induces symptomatic improvements in MG patients especially in generalized type. And the adverse events should be closely monitored.
|
Authors | Hui-yu Feng, Wei-bin Liu, Li Qiu, Xin Huang, Ru-xun Huang |
Journal | Zhonghua yi xue za zhi
(Zhonghua Yi Xue Za Zhi)
Vol. 91
Issue 45
Pg. 3190-2
(Dec 06 2011)
ISSN: 0376-2491 [Print] China |
PMID | 22333101
(Publication Type: Clinical Trial, English Abstract, Journal Article, Research Support, U.S. Gov't, Non-P.H.S.)
|
Chemical References |
- Immunosuppressive Agents
- Tacrolimus
|
Topics |
- Adult
- Female
- Humans
- Immunosuppressive Agents
(therapeutic use)
- Male
- Middle Aged
- Myasthenia Gravis
(drug therapy)
- Tacrolimus
(adverse effects, therapeutic use)
- Young Adult
|